Spots Global Cancer Trial Database for A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat
Official Title: Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)
Study ID: NCT02890069
Study Description
Brief Summary: The purpose of this study was to combine the PDR001 checkpoint inhibitor with several agents with immunomodulatory activity to identify the doses and schedule for combination therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical activity of these combinations.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
UCLA Santa Monica Hematology / Oncology SC, Santa Monica, California, United States
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
The Regents of the University of Michigan, Ann Arbor, Michigan, United States
Washington University Medical School SC, Saint Louis, Missouri, United States
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
UT Health San Antonio Mays Cancer Center, San Antonio, Texas, United States
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Seattle Cancer Care Alliance, Seattle, Washington, United States
Novartis Investigative Site, Jena, , Germany
Novartis Investigative Site, Ulm, , Germany
Novartis Investigative Site, Wuerzburg, , Germany
Novartis Investigative Site, Seoul, Korea, Korea, Republic of
Novartis Investigative Site, Seoul, , Korea, Republic of
Novartis Investigative Site, Amsterdam, , Netherlands
Novartis Investigative Site, Leiden, , Netherlands
Novartis Investigative Site, Rotterdam, , Netherlands
Novartis Investigative Site, Utrecht, , Netherlands
Novartis Investigative Site, Barcelona, Catalunya, Spain
Novartis Investigative Site, Pamplona, Navarra, Spain
Novartis Investigative Site, Madrid, , Spain
Novartis Investigative Site, Taipei, , Taiwan
Novartis Investigative Site, Sutton, Surrey, United Kingdom
Novartis Investigative Site, Manchester, , United Kingdom
Novartis Investigative Site, Oxford, , United Kingdom
Contact Details
Name: Novartis Pharmaceuticals
Affiliation: Novartis Pharmaceuticals
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
